200 results
Page 3 of 10
8-K
EX-99.2
8rvdv4ugtr 4bsu3
9 Nov 22
Entry into a Material Definitive Agreement
8:30am
424B5
y4ygbjqwq93qx
8 Nov 22
Prospectus supplement for primary offering
9:50pm
8-K
EX-99.1
tzevfoqj8ju n88x85x0
24 Oct 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
9:41am
424B5
2r87yz
29 Jul 22
Prospectus supplement for primary offering
5:09pm
424B5
komev34 pl83zf51
14 Jun 22
Prospectus supplement for primary offering
5:19pm
424B5
5u7d 5kh6np
14 Jun 22
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
oafybk81v
11 Mar 22
Bio-path Holdings Reports Full Year 2021 Financial Results
7:30am
8-K
EX-99.1
ynz tnk57i
13 Dec 21
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
7:40am
8-K
EX-99.1
g2bsfrar
12 Nov 21
Bio-Path Holdings Reports Third Quarter 2021 Financial Results
7:10am
8-K
EX-99.1
nosrl9f3hbp4wnecz4x0
4 Nov 21
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
12:00am
8-K
EX-99.1
ytmpy7w7
27 Oct 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
9:04am
8-K
EX-99.1
loikp1qut4o lv7h5cs
24 Aug 21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
8:29am
424B5
fv28kydd yw
19 Aug 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
cfk7qh44xu
13 Aug 21
Bio-Path Holdings Reports Second Quarter 2021 Financial Results
7:11am